Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical propertiesNicolas Boutard, Charles‐Henry Fabritius, Marcin Bień et al.|Bioorganic & Medicinal Chemistry Letters|2018Cited by 24
Discovery and Structure–Activity Relationships of <i>N</i>‐Aryl 6‐Aminoquinoxalines as Potent PFKFB3 Kinase InhibitorsNicolas Boutard, Charles‐Henry Fabritius, Arkadiusz Białas et al.|ChemMedChem|2018Cited by 22
Abstract 4231: Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatmentAnna Bartosik, Krzysztof Brzózka, Adam Radzimierski et al.|Cancer Research|2025Cited by 1